EA201001389A1 - Способ прогнозирования предрасположенности к развитию аддиктивного заболевания или расстройства (варианты) - Google Patents

Способ прогнозирования предрасположенности к развитию аддиктивного заболевания или расстройства (варианты)

Info

Publication number
EA201001389A1
EA201001389A1 EA201001389A EA201001389A EA201001389A1 EA 201001389 A1 EA201001389 A1 EA 201001389A1 EA 201001389 A EA201001389 A EA 201001389A EA 201001389 A EA201001389 A EA 201001389A EA 201001389 A1 EA201001389 A1 EA 201001389A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
sert
polymorphism
gene
options
Prior art date
Application number
EA201001389A
Other languages
English (en)
Other versions
EA019200B1 (ru
Inventor
Бэнкоул А. Джонсон
Original Assignee
Юниверсити Оф Вирджиния Пэтент Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Вирджиния Пэтент Фаундейшн filed Critical Юниверсити Оф Вирджиния Пэтент Фаундейшн
Publication of EA201001389A1 publication Critical patent/EA201001389A1/ru
Publication of EA019200B1 publication Critical patent/EA019200B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/307—Drug dependency, e.g. alcoholism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Ген, отвечающий за кодирование SERT, имеет функциональный полиморфизм в 5-регуляторной промоторной области, что приводит в результате к двум формам, длинной (L) и короткой (S). Предполагается, что LL генотип имеет важнейшее значение для раннего употребления алкоголя. Настоящее изобретение раскрывает различия в лечении и диагностике с учётом L или S генотипов, а также с учётом единичного нуклеотидного полиморфизма гена SERT, 3'- UTR SNP rs1042173. Настоящее изобретение демонстрирует эффективность применения лекарства ондансетрона и аналогичных лекарств для лечения с учётом вариантов в полиморфизме гена SERT, а также способы диагностики восприимчивости к алкоголемании (неудержимому стремлению к пьянству) и других аддиктивных заболеваний и расстройств.
EA201001389A 2008-02-28 2009-02-27 Способ прогнозирования предрасположенности к развитию аддиктивного заболевания или расстройства (варианты) EA019200B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3226308P 2008-02-28 2008-02-28
US5930108P 2008-06-06 2008-06-06
US14644009P 2009-01-22 2009-01-22
PCT/US2009/035420 WO2009108837A2 (en) 2008-02-28 2009-02-27 Serotonin transporter gene and treatment of alcoholism

Publications (2)

Publication Number Publication Date
EA201001389A1 true EA201001389A1 (ru) 2011-04-29
EA019200B1 EA019200B1 (ru) 2014-01-30

Family

ID=41016720

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001389A EA019200B1 (ru) 2008-02-28 2009-02-27 Способ прогнозирования предрасположенности к развитию аддиктивного заболевания или расстройства (варианты)

Country Status (19)

Country Link
US (10) US8697361B2 (ru)
EP (1) EP2255184B1 (ru)
JP (1) JP2011515076A (ru)
KR (1) KR20100127799A (ru)
CN (1) CN102016571A (ru)
AU (1) AU2009219174B2 (ru)
BR (1) BRPI0908425B8 (ru)
CA (1) CA2716498C (ru)
DK (1) DK2255184T3 (ru)
EA (1) EA019200B1 (ru)
ES (1) ES2430940T3 (ru)
HK (1) HK1151091A1 (ru)
HR (1) HRP20130621T1 (ru)
IL (1) IL207822A (ru)
MX (1) MX2010009509A (ru)
NZ (1) NZ588037A (ru)
PL (1) PL2255184T3 (ru)
WO (1) WO2009108837A2 (ru)
ZA (1) ZA201006485B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8631151B2 (en) 2006-05-18 2014-01-14 Intel Corporation Techniques for guaranteeing bandwidth with aggregate traffic
AU2007333656A1 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
US20100076006A1 (en) * 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
WO2009029308A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
KR20100127799A (ko) 2008-02-28 2010-12-06 유니버시티 오브 버지니아 페이턴트 파운데이션 세로토닌 운반체 유전자 및 알콜중독의 치료
US20120115149A1 (en) * 2009-05-01 2012-05-10 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
ES2664083T3 (es) 2010-07-02 2018-04-18 University Of Virginia Patent Foundation Enfoque genético molecular para el tratamiento y diagnóstico de la dependencia de alcohol y drogas
JP5899527B2 (ja) * 2011-03-14 2016-04-06 国立研究開発法人理化学研究所 第６染色体短腕２１．３３領域の一塩基多型に基づく抗てんかん薬による薬疹リスクの検査方法
EP2710152A4 (en) 2011-05-17 2015-04-08 Nat Ict Australia Ltd COMPUTER IMPLEMENTED METHOD AND SYSTEM FOR DETERMINING INTERCONNECTION OF THE DNA LOCI
EA027743B1 (ru) * 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
JP2015165780A (ja) * 2014-03-04 2015-09-24 大学共同利用機関法人情報・システム研究機構 視床−皮質軸索でｅｇｆｐを発現するマウス
ES2546896B1 (es) * 2014-03-26 2016-07-07 Universitat De Les Illes Balears Método para la predicción y/o la prevención de sobrepeso, obesidad y/o sus complicaciones mediante análisis de expresión génica
CN104615913B (zh) * 2014-12-31 2017-11-07 深圳先进技术研究院 一种标志物相关性检测方法以及装置
PL3273952T3 (pl) 2015-03-26 2022-11-14 SEN-JAM Pharmaceutical LLC Kombinacja naproksenu i feksofenadyny w celu zahamowania objawów związanych z zatruciem alkoholem
RU2695659C1 (ru) * 2018-09-28 2019-07-25 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ прогнозирования оценки эффективности терапии промазином для лечения расстройств, сопровождающихся развитием психотической симптоматики
KR101950372B1 (ko) * 2018-10-30 2019-02-20 한국화학연구원 스테로이드 대사 변화 분석 방법, 이에 따른 인터넷 또는 스마트폰 중독 예측방법 및 이를 실현하기 위한 프로그램이 저장된 컴퓨터 판독 가능한 기록 매체
RU2700565C1 (ru) * 2019-06-06 2019-09-19 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью Способ определения предрасположенности к развитию ожирения у детей в условиях избыточной контаминации алюминием
US20210043293A1 (en) * 2019-08-05 2021-02-11 RxAssurance Corporation (d/b/a OpiSafe) Techniques for providing interactive clinical decision support for drug dosage reduction
KR102203807B1 (ko) * 2019-08-05 2021-01-15 한국과학기술연구원 중독의 진단용 조성물, 키트 및 이를 이용한 중독의 진단을 위한 세로토닌의 검출 방법
RU2722834C1 (ru) * 2019-12-19 2020-06-04 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ прогнозирования оценки эффективности терапии флувоксамином для лечения расстройств, сопровождающихся развитием депрессивной симптоматики
EP4076433A4 (en) * 2019-12-20 2023-09-27 The Jackson Laboratory MOLECULAR TARGETS FOR ADDICTION
CN112002375B (zh) * 2020-07-30 2022-10-14 苏州因顿医学检验实验室有限公司 一种酒量预测模型的构建方法
US20220117916A1 (en) * 2020-10-19 2022-04-21 SafeRx Pharmaceuticals, LLC Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose
RU2753899C1 (ru) * 2020-11-23 2021-08-24 Александр Борисович Мулик Способ прогнозирования риска развития алкоголизации населения локальных территорий
WO2022117573A1 (en) * 2020-12-01 2022-06-09 Fundació Institut De Recerca De L'hospital De La Santa Creu I Sant Pau Predicting behavioural addictions
RU2767699C1 (ru) * 2021-09-02 2022-03-18 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Способ прогнозирования коморбидного течения аффективных расстройств и алкоголизма на основе определения белков сыворотки крови

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA219554A (en) 1922-06-13 Edward A. Taft Knot tying implement
US5550021A (en) * 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
RU2075978C1 (ru) 1994-03-21 1997-03-27 Владислав Ефимович Шофер Способ лечения больных хроническим алкоголизмом
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
EP0945133A1 (en) 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US20040167164A1 (en) * 1998-05-05 2004-08-26 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
CA2362533A1 (en) 1999-02-22 2000-08-31 Variagenics, Inc. Gene sequence variations with utility in determining the treatment of disease
JP2002537326A (ja) * 1999-02-24 2002-11-05 ユニヴァーシティ・オブ・シンシナティ 衝動調節障害の治療のためのスルファメート誘導体の使用
US20040006488A1 (en) * 2000-09-29 2004-01-08 Simon Fitall Creation of a database containing personal health care profiles
US7122308B2 (en) * 2001-02-16 2006-10-17 Centre For Addiction And Mental Health Detection of antidepressant induced mania
US7033771B2 (en) * 2001-05-08 2006-04-25 Takeda Pharmaceutical Company Limited Use of insulin response modulators in the treatment of diabetes and insulin resistance
EP1262196A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
RU2004107501A (ru) * 2001-08-14 2005-02-20 Байотай Терапис Корпорейшн (Fi) Способ лечения алкоголизма или злоупотребления алкоголем
US20030100479A1 (en) * 2001-08-21 2003-05-29 Dow David J. Gene polymorphisms and response to treatment
US20030114475A1 (en) * 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
WO2003097873A2 (en) 2002-05-15 2003-11-27 Epidauros Biotechnologie Ag Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
AU2003237657A1 (en) 2002-05-24 2003-12-12 Epidauros Biotechnologie Ag Means and methods for improved treatment using "setrones"
MXPA05011557A (es) * 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7163969B2 (en) * 2003-10-14 2007-01-16 Stockhausen, Inc. Superabsorbent polymer aqueous paste and coating
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
WO2007009691A2 (en) 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti -addictive agent
WO2007039123A2 (en) 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
RU2008116720A (ru) * 2005-09-26 2009-11-10 Эвиджен, Инк. (Us) Способы лечения наркозависимости и пагубных привычек в поведении
US20070196841A1 (en) 2006-01-20 2007-08-23 Gualberto Ruano Physiogenomic method for predicting response to diet
US8026059B2 (en) * 2006-02-15 2011-09-27 The Regents Of The University Of California Treatment response in generalized social phobia
US20070292880A1 (en) * 2006-05-05 2007-12-20 Robert Philibert Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
AU2007333656A1 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
US20100076006A1 (en) * 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
US7844609B2 (en) * 2007-03-16 2010-11-30 Expanse Networks, Inc. Attribute combination discovery
EP2178519B1 (en) 2007-07-13 2012-04-25 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
US20110264374A1 (en) * 2007-08-21 2011-10-27 University Of Virginia Patent Foundation Method, Computer Program Product and System for Individual Assessment of Alcohol Sensitivity
WO2009029308A1 (en) 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
KR20100127799A (ko) 2008-02-28 2010-12-06 유니버시티 오브 버지니아 페이턴트 파운데이션 세로토닌 운반체 유전자 및 알콜중독의 치료
WO2009134944A2 (en) * 2008-04-29 2009-11-05 Nodality, Inc. Methods of determining the health status of an individual
US20120115149A1 (en) * 2009-05-01 2012-05-10 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
ES2664083T3 (es) 2010-07-02 2018-04-18 University Of Virginia Patent Foundation Enfoque genético molecular para el tratamiento y diagnóstico de la dependencia de alcohol y drogas
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
US10997121B1 (en) 2020-07-17 2021-05-04 Snowflake Inc. Attachable-and-detachable database sessions

Also Published As

Publication number Publication date
HK1151091A1 (en) 2012-01-20
US10995374B2 (en) 2021-05-04
ZA201006485B (en) 2014-02-26
IL207822A0 (en) 2010-12-30
JP2011515076A (ja) 2011-05-19
US11905562B2 (en) 2024-02-20
BRPI0908425A2 (pt) 2015-08-04
EP2255184B1 (en) 2013-04-24
US20110112159A1 (en) 2011-05-12
CA2716498C (en) 2020-12-22
US20170226585A1 (en) 2017-08-10
US20190249255A1 (en) 2019-08-15
IL207822A (en) 2015-09-24
US20200199679A1 (en) 2020-06-25
EP2255184A4 (en) 2011-08-31
US10619209B2 (en) 2020-04-14
WO2009108837A2 (en) 2009-09-03
EA019200B1 (ru) 2014-01-30
ES2430940T3 (es) 2013-11-22
NZ588037A (en) 2012-08-31
BRPI0908425B8 (pt) 2021-05-25
DK2255184T3 (da) 2013-07-22
EP2255184A2 (en) 2010-12-01
US8697361B2 (en) 2014-04-15
AU2009219174B2 (en) 2014-04-03
CN102016571A (zh) 2011-04-13
US20180251840A1 (en) 2018-09-06
US10533226B2 (en) 2020-01-14
US20160139161A1 (en) 2016-05-19
US20190002984A1 (en) 2019-01-03
CA2716498A1 (en) 2009-09-03
WO2009108837A3 (en) 2009-12-30
US20210301346A1 (en) 2021-09-30
US20160376658A1 (en) 2016-12-29
MX2010009509A (es) 2010-11-30
AU2009219174A1 (en) 2009-09-03
BRPI0908425B1 (pt) 2021-03-09
PL2255184T3 (pl) 2013-12-31
US20140206734A1 (en) 2014-07-24
HRP20130621T1 (en) 2013-09-30
KR20100127799A (ko) 2010-12-06

Similar Documents

Publication Publication Date Title
EA201001389A1 (ru) Способ прогнозирования предрасположенности к развитию аддиктивного заболевания или расстройства (варианты)
WO2009059318A3 (en) Genes and polymorphisms associated with amd
EA201170332A1 (ru) Способ идентификации факторов риска заболеваний
ATE551350T1 (de) Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
WO2010062960A3 (en) METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2011133477A3 (en) Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
PL2084535T3 (pl) Bioinformatyczne podejście do diagnozy choroby
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
NZ589034A (en) Detecting genetic predisposition to osteoarthritis associated conditions
WO2007095580A3 (en) Treatment response in generalized social phobia
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
WO2010047938A3 (en) Mmp activation peptide detection in biological samples
EA201390017A1 (ru) Молекулярно-генетический подход к лечению и диагностике алкогольной и наркотической зависимости
WO2006003523A8 (en) Human autism susceptibility gene encoding prkcb1 and uses thereof
WO2008076434A3 (en) Predicting a response to risperidone
WO2008052016A3 (en) The sortilin-related receptor sorl1 is functionally and genetically associated with alzheimer's disease
WO2008070311A3 (en) Gene expression profiling of parkinson's disease
DK1863937T3 (da) Humant autisme-susceptibilitetsgen kodende for et transmembranprotein og anvendelser deraf
WO2005067708A3 (en) Zebrafish model for autoimmune diseases
WO2011112859A3 (en) Methods relating to olanzapine pharmacogenetics
UA103893C2 (ru) Ген транспортера серотонина и способы прогнозирования склонности к развитию связанной с алкоголем болезни или расстройства, способы прогнозирования реакции на лечение и способы лечения соответствующих болезней
WO2010097706A3 (en) Methods and compositions for evaluating chronic immune diseases
MX2013013023A (es) Analisis y metodo para la identificacion de la capacidad de respuestas individual a tratamiento con inmunoglobulina.
WO2007122279A3 (es) Método de análisis de haplotipos para el diagnóstico o pronostico de patologías que cursen con distrofia retiniana